Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew N Billin

Showing results (31-40 of 55) with videos related to

Pageof 6
Sort By:
Genes & Development|June 20, 2003
Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesisJason A Holt, Guizhen Luo, Andrew N Billin, et al.
Bioorganic & Medicinal Chemistry Letters|August 30, 2008
Discovery of a novel class of PPARdelta partial agonistsBarry G Shearer, Hari S Patel, Andrew N Billin, et al.
The Journal of Biological Chemistry|March 4, 2003
Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genesJodi M Maglich, Derek J Parks, Linda B Moore, et al.
Journal of Hepatology|April 19, 2022
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trialNaim Alkhouri, Robert Herring, Heidi Kabler, et al.
American Journal of Physiology. Endocrinology and Metabolism|November 21, 2013
Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cellsMara Fornaro, Aaron C Hinken, Saul Needle, et al.
Hepatology (Baltimore, Md.)|August 4, 2020
A Fibrosis-Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing CholangitisYevgeniy Gindin, Chuhan Chung, Zhaoshi Jiang, et al.
Journal of Medicinal Chemistry|February 5, 2010
Identification and characterization of 4-chloro-N-(2-{[5-trifluoromethyl)-2-pyridyl]sulfonyl}ethyl)benzamide (GSK3787), a selective and irreversible peroxisome proliferator-activated receptor delta (PPARdelta) antagonistBarry G Shearer, Robert W Wiethe, Adam Ashe, et al.
Bioorganic & Medicinal Chemistry Letters|May 30, 2007
Co-crystal structure guided array synthesis of PPARgamma inverse agonistsRyan P Trump, Jeffrey E Cobb, Barry G Shearer, et al.
Gastroenterology|November 10, 2025
The ANTICIPATE-NASH Models Stratify Better the Risk of Clinical Events Than Histology in Metabolic Dysfunction-Associated Steatotic Liver Disease Patients With Advanced Chronic Liver DiseaseLaia Aceituno, Juan Bañares, Mònica Pons, et al.
Hepatology (Baltimore, Md.)|May 13, 2022
Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLDEkaterina Smirnova, Mark D Muthiah, Nicole Narayan, et al.
Pageof 6

Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
Genes & Development|June 20, 2003
Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesisJason A Holt, Guizhen Luo, Andrew N Billin, et al.
Bioorganic & Medicinal Chemistry Letters|August 30, 2008
Discovery of a novel class of PPARdelta partial agonistsBarry G Shearer, Hari S Patel, Andrew N Billin, et al.
The Journal of Biological Chemistry|March 4, 2003
Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genesJodi M Maglich, Derek J Parks, Linda B Moore, et al.
Journal of Hepatology|April 19, 2022
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trialNaim Alkhouri, Robert Herring, Heidi Kabler, et al.
American Journal of Physiology. Endocrinology and Metabolism|November 21, 2013
Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cellsMara Fornaro, Aaron C Hinken, Saul Needle, et al.
Hepatology (Baltimore, Md.)|August 4, 2020
A Fibrosis-Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing CholangitisYevgeniy Gindin, Chuhan Chung, Zhaoshi Jiang, et al.
Journal of Medicinal Chemistry|February 5, 2010
Identification and characterization of 4-chloro-N-(2-{[5-trifluoromethyl)-2-pyridyl]sulfonyl}ethyl)benzamide (GSK3787), a selective and irreversible peroxisome proliferator-activated receptor delta (PPARdelta) antagonistBarry G Shearer, Robert W Wiethe, Adam Ashe, et al.
Bioorganic & Medicinal Chemistry Letters|May 30, 2007
Co-crystal structure guided array synthesis of PPARgamma inverse agonistsRyan P Trump, Jeffrey E Cobb, Barry G Shearer, et al.
Gastroenterology|November 10, 2025
The ANTICIPATE-NASH Models Stratify Better the Risk of Clinical Events Than Histology in Metabolic Dysfunction-Associated Steatotic Liver Disease Patients With Advanced Chronic Liver DiseaseLaia Aceituno, Juan Bañares, Mònica Pons, et al.
Hepatology (Baltimore, Md.)|May 13, 2022
Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLDEkaterina Smirnova, Mark D Muthiah, Nicole Narayan, et al.
Pageof 6